Boston Scientific owns more than 30% of the emphysema treatment device developer, which is targeting $86.3m in its offering.

Digital marketing platform developer Optimizely has agreed to be bought after raising $200m from investors including Citi, Salesforce, Accenture and Alphabet.

QuantaMatrix is targeting $17.80 to $22.30 per share under a regulation permitting a listing on the basis of growth and technology potential.

UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.

The solid-state battery developer, which has raised $300m from Volkswagen since 2018, will list on the New York Stock Exchange through a reverse merger deal.

Centerbridge has led a $178m round as part of a primary and secondary share purchase that will give it a majority stake in the Aegon and Transamerica-backed lending platform.

The CNS disease drug developer has filed to raise up to $100m in an initial public offering, just weeks after raising $96m from investors including GV.

Stanford spinout QuantumScape is set to merge with NYSE-listed Kensington Capital Acquisition in a $700m deal that will value the combined company at $3.3bn.

Al Faisaliah-backed affordable e-commerce platform developer Awok has confirmed it has ceased operations, less than 18 months after a $30m series A round.

Telstra, Liberty Global, Kraft Group and 32 Equity are set to exit esports competition platform Skillz in a deal valuing it at $3.5bn.